STOCK TITAN
  1. Home
  2. News
  3. RDHL

Redhill Biopharm - RDHL STOCK NEWS

Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.

Company Overview

RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies for gastrointestinal, infectious, and oncological diseases. With a focus on late clinical-stage development and patented drug formulations, the company leverages extensive expertise in clinical research, regulatory strategy, and commercial operations to address unmet medical needs.

Core Business and Market Position

RedHill Biopharma excels in advancing therapeutic candidates from concept to market. Its dual approach of improving existing drugs and pioneering new therapeutic candidates has established a robust pipeline. The company’s flagship products include Talicia, a novel treatment for Helicobacter pylori infections, and Aemcolo, targeted for travelers' diarrhea. Alongside these commercially marketed drugs, RedHill is actively advancing a number of clinical-stage programs such as opaganib, a first‐in‐class, orally administered sphingosine kinase-2 selective inhibitor, and several other candidates (RHB-107, RHB-102, RHB-104, RHB-204) aimed at addressing critical indications in oncology, viral infections, radiation protection, and inflammatory diseases.

Research and Development Excellence

Emphasizing rigorous research and robust clinical validation, RedHill’s R&D strategy leverages both internal expertise and strategic collaborations with U.S. government agencies and leading academic institutions. The company’s clinical trials and research programs are designed to meet the rigorous standards expected in the biopharmaceutical industry, enhancing its credibility and establishing its authority in the field. Through its focus on clinical efficacy, safety, and patented drug formulations, RedHill reinforces its commitment to innovative therapies and patient outcomes.

Operational Strengths and Competitive Differentiators

A key strength of RedHill is its experienced management team, which includes seasoned professionals from Israel, the U.S., Canada, and Europe. Their combined expertise in regulatory affairs, commercialization, and transactional experience allows the company to execute cost-efficient strategies while positioning its products favorably in a competitive market. This balanced approach not only strengthens its current market offering but also ensures continuous innovation and resilience in the face of industry challenges.

Investor and Market Relevance

For investors and market analysts, RedHill Biopharma represents a compelling blend of commercial successes and forward-looking clinical development programs. The company’s strategic focus on gastrointestinal and infectious therapies, combined with its robust pipeline and global network of expertise, underscores its value as a differentiated player in the specialty biopharmaceutical sector. Through its comprehensive approach to product development and commercialization, RedHill continues to solidify its position within a competitive and evolving market landscape.

News

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Rhea-AI Summary
RedHill Biopharma focuses on U.S. government-funded pipeline development in underserved therapeutic areas with opaganib and RHB-107 advancing in externally funded R&D programs. Opaganib shows promise for nuclear and chemical medical countermeasures, Ebola, and COVID-19, while RHB-107 targets COVID-19 and Ebola. Financially, RedHill reports a cash balance of $6.5 million, gross profit of $3.1 million, and operating income of $12.6 million for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
earnings
-
News

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Rhea-AI Summary
RedHill Biopharma (RDHL) announces a registered direct offering with private investors for the purchase and sale of 2,144,487 ADSs and warrants at a premium price of $0.58289 per ADS. The offering represents a 10% premium over the closing price on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
offering
-
News

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

Rhea-AI Summary
RedHill Biopharma Ltd. announces the issuance of a new U.S. patent covering Talicia as an all-in-one treatment for H. pylori infection, providing protection until February 2034. Talicia is the only FDA-approved rifabutin-containing therapy for H. pylori eradication, with an optimized resistance profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
none
News

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Rhea-AI Summary
RedHill Biopharma's opaganib selected by U.S. government for evaluation as a medical countermeasure against Sulfur Mustard exposure. Opaganib, a novel oral small molecule, shows promise for multiple indications including COVID-19 and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
News

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces promising results of opaganib in treating radiation-induced lung inflammation and fibrosis. Opaganib, a selective SPHK2 inhibitor, significantly improved long-term survival in an in vivo mouse model post ionizing radiation exposure. The data suggest its potential as a medical countermeasure for radiation and cancer therapy. Opaganib is being evaluated for Acute Radiation Syndrome (ARS) and other indications like COVID-19, ARDS, filoviruses, and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
-
News

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Rhea-AI Summary
RedHill Biopharma Ltd. (NASDAQ: RDHL) has closed a registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS, with gross proceeds of $8 million. The Company also issued unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The net proceeds will be used for general working capital, acquisitions, research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
offering
News

RedHill Biopharma Announces $8 Million Registered Direct Offering

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered into agreements for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS in a registered direct offering. Additionally, the Company will issue unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
offering
-
News

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Rhea-AI Summary
RedHill Biopharma Ltd. announces the issuance of a new patent by the USPTO covering Talicia as a method for eradicating H. pylori regardless of patient BMI, providing protection until May 2042. The patent is supported by previously published data showing Talicia's efficacy was unaffected by elevated BMI. Talicia has been granted market exclusivity for five years under the GAIN Act QIDP designation, in addition to three years' exclusivity granted for its approval under section 505(b)(2). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori eradication, a bacterial infection affecting approximately 35% of the U.S. adult population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
none
-
News

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces positive in vitro results for investigational drugs opaganib and RHB-107 in combination with remdesivir, showing a distinct synergy in viral inhibition while maintaining cell viability. Opaganib and RHB-107 are expected to be effective against multiple viral targets, including COVID-19 and emerging viral variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
News

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing. The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving compliance on December 8, 2023. This comes after previously receiving notification that the bid price for the American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none

FAQ

What is the current stock price of Redhill Biopharm (RDHL)?

The current stock price of Redhill Biopharm (RDHL) is $2.24 as of April 23, 2025.

What is the market cap of Redhill Biopharm (RDHL)?

The market cap of Redhill Biopharm (RDHL) is approximately 3.8M.

What is the primary focus of RedHill Biopharma?

RedHill Biopharma focuses on developing and commercializing therapies for gastrointestinal diseases, infectious diseases, and oncology through both innovative clinical-stage programs and proven commercial products.

Which products does RedHill currently commercialize?

The company promotes products like Talicia for the treatment of Helicobacter pylori infections and Aemcolo for travelers' diarrhea, addressing key gastrointestinal disorders.

What are some of the key clinical programs in RedHill's pipeline?

Key clinical candidates include opaganib, a first-in-class sphingosine kinase-2 inhibitor, and additional candidates such as RHB-107, RHB-102, RHB-104, and RHB-204, targeting various indications from oncology to pandemic preparedness.

How does RedHill differentiate itself in the biopharmaceutical industry?

The company differentiates itself through its focus on late-stage drug development, a dual strategy of enhancing existing therapies and developing new candidates, and a management team with global experience and a strong track record in pharma.

Why is RedHill considered an expert in clinical-stage drug development?

RedHill’s extensive R&D collaborations, rigorous clinical trials, patented drug formulations, and a highly experienced international team bolster its authority and expertise in the field.

What makes RedHill Biopharma attractive to investors?

Investors are drawn to RedHill due to its balanced blend of proven commercial products and a diversified, advanced clinical pipeline, backed by a strong research foundation and global operational expertise.
Stock RDHL logo
Redhill Biopharm

Nasdaq:RDHL

RDHL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RDHL Stock Data

3.78M
1.77M
6.77%
2.62%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv